Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy and safety of IDH inhibitors in IDH-mutated cancers: a systematic review and meta-analysis of 4 randomized controlled trials.

World journal of surgical oncology - 7 Nov 2024

Cai Zelin, Yang Huiting, Yu Zhuoran, Su Jingyang, Zhang Jie, Ye Zhifeng, Hu Keke, Huang Ting, Zhou Heran

Abstract excerpt

BACKGROUND: Isocitrate dehydrogenase (IDH) inhibitors have shown great promise in the treatment of cancers with IDH mutations. There have been numerous clinical trials conducted on IDH inhibitors, and to evaluate their efficacy and safety, we aim to perform a meta-analysis. METHODS: To gather data on the efficacy and safety of IDH inhibitors for IDH-mutated cancers, we systematically searched through databases...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Enzyme Inhibitors
Share to Isocitrate Dehydrogenase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasms

Share to Prognosis

Share to Randomized Controlled Trials as Topic

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 39511636
DOI: 10.1186/s12957-024-03579-z
PMCID: PMC11546319

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy and safety of IDH inhibitors in IDH-mutated cancers: a systematic review and meta-analysis of 4 randomized controlled trials.PMID 39511636Read ↗

Efficacy and safety of FDA-approved IDH inhibitors in the treatment of IDH mutated acute myeloid leukemia: a systematic review and meta-analysis.Semantic proximity Read ↗

The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancerSemantic proximity Read ↗

Biological Roles and Therapeutic Applications of IDH2 Mutations in Human CancerSemantic proximity Read ↗

Clinical development of IDH1 inhibitors for cancer therapy.Semantic proximity Read ↗

Discovery of novel natural-product-derived mutant isocitrate dehydrogenases 1 inhibitors: Structure-based virtual screening, biological evaluation and structure-activity relationship study.Semantic proximity Read ↗

Recent advances of IDH1 mutant inhibitor in cancer therapySemantic proximity Read ↗

Biological Role and Therapeutic Potential of IDH Mutations in Cancer.Semantic proximity Read ↗

Therapeutic inhibition of isocitrate dehydrogenase mutations in glioma and cholangiocarcinoma: new insights and promises-a narrative review.Semantic proximity Read ↗

Wild-Type IDH Enzymes as Actionable Targets for Cancer TherapySemantic proximity Read ↗

Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective.Semantic proximity Read ↗

Real-World Outcomes of Ivosidenib in IDH1-Mutant Biliary Tract Cancer: A Multicenter Retrospective Analysis and Comparison with the TrinetX Database.Semantic proximity Read ↗

Isocitrate Dehydrogenase Inhibitors in Acute Myeloid Leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.